natgillin/translations-raw huggingface dataset:
Consequently, pursuant to Article 7(2) of Regulation (EC) No 1670/2006, this should be taken into account in calculating the coefficients for 2013/2014,
V skladu s členom 7(2) Uredbe (ES) št. 1670/2006 je treba to upoštevati pri izračunavanju koeficienta za obdobje 2013/2014 –
For the period 1 October 2013 to 30 September 2014, the coefficients provided for in Article 4 of Regulation (EC) No 1670/2006 applying to cereals used in the United Kingdom for producing Scotch whisky shall be as set out in the Annex to this Regulation.
Za obdobje od 1. oktobra 2013 do 30. septembra 2014 so koeficienti iz člena 4 Uredbe (ES) št. 1670/2006, ki se uporabijo za žita, uporabljena v Združenem kraljestvu za proizvodnjo škotskega viskija, določeni v Prilogi k tej uredbi.
It shall apply from 1 October 2013 to 30 September 2014.
Uporablja se od 1. oktobra 2013 do 30. septembra 2014.
Commission Implementing Regulation (EU) No 745/2012 of 16 August 2012 fixing the coefficients applicable to cereals exported in the form of Scotch whisky for the period 2012/2013 (OJ L 219, 17.8.2012, p. 13).
Izvedbena uredba Komisije (EU) št. 745/2012 z dne 16. avgusta 2012 o določitvi koeficientov, ki se za obdobje 2012/2013 uporabljajo za žito, izvoženo v obliki škotskega viskija (UL L 219, 17.8.2012, str. 13).
From 1 October 2013 to 30 September 2014
od 1. oktobra 2013 do 30. septembra 2014
Commission Implementing Regulation (EU) No 745/2012 [3] has ceased to be operative given that it concerns the coefficients applicable for the year 2012/2013.
Izvedbena uredba Komisije (EU) št. 745/2012 [3] je brezpredmetna, saj se nanaša na koeficiente, ki so se uporabljali za leto 2012/2013.
The coefficients for the period 1 October 2013 to 30 September 2014 should therefore be fixed accordingly.
Zato bi bilo treba določiti koeficiente za obdobje od 1. oktobra 2013 do 30. septembra 2014.
Commission Regulation (EU) No 1065/2013
Uredba Komisije (EU) št. 1065/2013
Having regard to Regulation (EC) No 110/2008 of the European Parliament and of the Council of 15 January 2008 on the definition, description, presentation, labelling and the protection of geographical indications of spirit drinks and repealing Council Regulation (EEC) No 1576/89 [1], and in particular Article 17(8) thereof,
ob upoštevanju Uredbe (ES) št. 110/2008 Evropskega parlamenta in Sveta z dne 15. januarja 2008 o opredelitvi, opisu, predstavitvi, označevanju in zaščiti geografskih označb žganih pijač ter razveljavitvi Uredbe Sveta (EGS) št. 1576/89 [1] in zlasti člena 17(8) Uredbe,
The Republic of Peru has applied for the registration of ‘Pisco’ as a geographical indication in Annex III to Regulation (EC) No 110/2008, in accordance with the procedure laid down in Article 17(1) of that Regulation.
Republika Peru je vložila zahtevek za registracijo geografske označbe „Pisco“ v Prilogi III k Uredbi (ES) št. 110/2008 v skladu s postopkom, ki ga določa člen 17(1) navedene uredbe.
‘Pisco’ is a fruit spirit traditionally produced in Peru, from the fermentation and distillation of grapes.
„Pisco“ je žganje iz sadja, ki ga po tradicionalnih postopkih proizvajajo v Peruju s fermentacijo in destilacijo grozdja.
The main specifications of the technical file for ‘Pisco’ were published in the Official Journal of the European Union [2] for the purposes of the objection procedure, pursuant to Article 17(6) of Regulation (EC) No 110/2008.
Glavne specifikacije tehnične dokumentacije za pijačo „Pisco“ so bile objavljene v Uradnem listu Evropske unije [2] za namene postopka ugovora v skladu s členom 17(6) Uredbe (ES) št. 110/2008.
As the Commission did not receive any objections in accordance with Article 17(7) of Regulation (EC) No 110/2008, that name should be included in Annex III to that Regulation.
Ker Komisija v skladu s členom 17(7) Uredbe (ES) št. 110/2008 ni prejela nobenih ugovorov, bi bilo treba to ime vključiti v Prilogo III k navedeni uredbi.
According to the Agreement establishing an association between the European Community and its Member States, of the one part, and the Republic of Chile, of the other part, approved by Council Decision 2002/979/EC [3], ‘Pisco’ is a protected designation for spirit drinks originating in Chile.
Glede na Sporazum o pridružitvi med Evropsko skupnostjo in njenimi državami članicami na eni strani ter Republiko Čile na drugi, odobren s Sklepom Sveta 2002/979/ES [3], je „Pisco“ zaščitena označba za žgane pijače, ki izvirajo iz Čila.
Therefore, it should be clarified that the protection of the geographical indication ‘Pisco’ for products originating in Peru does not hinder the use of such denomination for products originating in Chile.
Zato bi bilo treba pojasniti, da zaščita geografske označbe „Pisco“ za proizvode, ki izvirajo iz Peruja, ne preprečuje rabe te označbe za proizvode, ki izvirajo iz Čila.
Regulation (EC) No 110/2008 should therefore be amended accordingly.
Uredbo (ES) št. 110/2008 bi bilo zato treba ustrezno spremeniti.
In Annex III to Regulation (EC) No 110/2008, in product category ‘9. Fruit spirit’, the following entry is added:
V Prilogi III k Uredbi (ES) št. 110/2008, v kategoriji proizvoda „9. žganje iz sadja“, se doda naslednji vnos:
OJ C 141, 12.5.2011, p. 16.
UL C 141, 12.5.2011, str. 16.
The protection of the geographical indication “Pisco” under this Regulation shall be without prejudice to the use of the name “Pisco” for products originating in Chile protected under the Association Agreement between the Union and Chile of 2002.
Zaščita geografske označbe ‚Pisco‘ iz te uredbe ne vpliva na uporabo imena ‚Pisco‘ za proizvode, ki izvirajo iz Čila in jih ščiti Pridružitveni sporazum EU-Čile iz leta 2002.
Commission Regulation (EU) No 1066/2013
Uredba Komisije (EU) št. 1066/2013
The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as ‘the Authority’ for a scientific assessment, as well as to the Commission and the Member States for information.
Pristojni nacionalni organ veljavne vloge pošlje Evropski agenciji za varnost hrane (v nadaljnjem besedilu: Agencija) za znanstveno oceno ter Komisiji in državam članicam v vednost.
The Authority is to deliver an opinion on the health claim concerned.
Agencija pripravi mnenje o zadevni zdravstveni trditvi.
Following an application from Béres Pharmaceuticals Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of glucosamine and maintenance of joints (Question No EFSA-Q-2011-00907) [2].
Družba Béres Pharmaceuticals Ltd. je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki glukozamina na ohranjanje funkcije sklepov (vprašanje št. EFSA-Q-2011-00907) [2].
The claim proposed by the applicant was worded as follows: ‘Glucosamine contributes to the protection of joint cartilage exposed to excessive motion or loading and helps to improve the range of motion in joints’.
Vložnik je predlagal naslednjo trditev: „Glukozamin prispeva k zaščiti sklepnega hrustanca, izpostavljenega prekomernemu gibanju ali obremenitvi, in pomaga izboljšati obseg premikanja sklepov.“
On 5 December 2011, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of glucosamine and the claimed effect.
Komisija in države članice so 5. decembra 2011 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem glukozamina in navedeno trditvijo ni utemeljena.
Following an application from Merck Consumer Healthcare, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of glucosamine and maintenance of normal joint cartilage (Question No EFSA-Q-2011-01113) [3].
Družba Merck Consumer Healthcare je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki glukozamina na ohranjanje normalnega sklepnega hrustanca (vprašanje št. EFSA-Q-2011-01113) [3].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Glucosamine contributes to the maintenance of normal joint cartilage’.
Vložnik je med drugim predlagal naslednjo trditev: „Glukozamin prispeva k ohranjanju normalnega sklepnega hrustanca.“
On 16 May 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of glucosamine and the claimed effect.
Komisija in države članice so 16. maja 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem glukozamina in navedeno trditvijo ni utemeljena.
Following an application from Extraction Purification Innovation France, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the consumption of wheat polar lipid extract and protection of the skin against dehydration (Question No EFSA-Q-2011-01122) [4].
Družba Extraction Purification Innovation France je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z uživanjem izvlečka polarnega lipida iz pšenice in zaščito kože pred dehidracijo (vprašanje št. EFSA-Q-2011-01122) [4].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Contributes to improve skin hydration’.
Vložnik je med drugim predlagal naslednjo trditev: „Prispeva k izboljšanju hidracije kože“.
On 5 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of wheat polar lipid extract and the claimed effect.
Komisija in države članice so 5. julija 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izvlečka polarnega lipida iz pšenice in navedeno trditvijo ni utemeljena.
Following an application from Lesaffre International/Lesaffre Human Care, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Saccharomyces cerevisiae var. boulardii CNCM I-3799 and reducing gastro-intestinal discomfort (Question No EFSA-Q-2012-00271) [5].
Družba Lesaffre International/Lesaffre Human Care je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Saccharomyces cerevisiae var. boulardii CNCM I-3799 na zmanjšanje prebavnih motenj (vprašanje št. EFSA-Q-2012-00271) [5].
The claim proposed by the applicant was worded as follows: ‘Saccharomyces cerevisiae var. boulardii CNCM I-3799 helps maintain intestinal comfort’.
Vložnik je predlagal naslednjo trditev: „Saccharomyces cerevisiae var. boulardii CNCM I-3799 pomaga vzdrževati črevesno udobje“.
On 17 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship could not be established between the consumption of Saccharomyces cerevisiae var. boulardii CNCM I-3799 and the claimed effect.
Komisija in države članice so 17. julija 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledične povezave med uživanjem Saccharomyces cerevisiae var. boulardii CNCM I-3799 in navedeno trditvijo ni bilo mogoče utemeljiti.
Following two applications from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, D-biotin and pumpkin seed oil (Cucurbita pepo L.) and maintenance of normal hair (Question No EFSA-Q-2012-00334 and EFSA-Q-2012-00335) [6].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila dve vlogi, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki mešanice tiamina, riboflavina, niacina, pantotenske kisline, piridoksina, D-biotina in bučnega olja (Cucurbita pepo L.) na ohranjanje zdravih las (vprašanji št. EFSA-Q-2012-00334 in EFSA-Q-2012-00335) [6].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to increase hair number’.
Vložnik je med drugim predlagal naslednjo trditev: „Pomaga povečati število las“.
On 17 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, D-biotin and pumpkin seed oil (Cucurbita pepo L.) and the claimed effect.
Komisija in države članice so 17. julija 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem mešanice tiamina, riboflavina, niacina, pantotenske kisline, piridoksina, D-biotina in bučnega olja (Cucurbita pepo L.) ter navedeno trditvijo ni utemeljena.
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Rhodiola rosea L. extract and reduction of mental fatigue (Question No EFSA-Q-2012-00336) [7].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki izvlečka Rhodiola rosea L. na zmanjšanje psihične utrujenosti (vprašanje št. EFSA-Q-2012-00336) [7].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to reduce tiredness in case of stress’.
Vložnik je med drugim predlagal naslednjo trditev: „Pomaga zmanjšati utrujenost v primeru stresa“.
On 17 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Rhodiola rosea L. extract and the claimed effect.
Komisija in države članice so 17. julija 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izvlečkom Rhodiola rosea L. in navedeno trditvijo ni utemeljena.
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of flaxseed oil and vitamin E and maintenance of the skin permeability barrier function (Question No EFSA-Q-2012-00337) [8].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki mešanice lanenega olja in vitamina E na ohranjanje pregradne funkcije prepustnosti kože (vprašanje št. EFSA-Q-2012-00337) [8].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Contributes to maintain skin permeability barrier function’.
Vložnik je med drugim predlagal naslednjo trditev: „Prispeva k ohranjanju pregradne funkcije prepustnosti kože“.
On 17 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of flaxseed oil and vitamin E and the claimed effect.
Komisija in države članice so 17. julija 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem mešanice lanenega olja in vitamina E ter navedeno trditvijo ni utemeljena.
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of OptiEFAX™ and maintenance of normal blood LDL-cholesterol concentrations (Question No EFSA-Q-2012-00339) [9].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki OptiEFAX™ na vzdrževanje normalne koncentracije LDL-holesterola v krvi (vprašanje št. EFSA-Q-2012-00339) [9].
The claim proposed by the applicant was worded as follows: ‘OptiEFAX™ helps to maintain healthy blood levels of LDL cholesterol’.
Vložnik je predlagal naslednjo trditev: „OptiEFAX™ pomaga vzdrževati zdrave ravni LDL-holesterola v krvi.“
On 17 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of OptiEFAX™ and the claimed effect.
Komisija in države članice so 17. julija 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem OptiEFAX™ in navedeno trditvijo ni utemeljena.
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of OptiEFAX™ and maintenance of normal blood HDL-cholesterol concentrations (Question No EFSA-Q-2012-00340) [10].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki OptiEFAX™ na vzdrževanje normalne koncentracije HDL-holesterola v krvi (vprašanje št. EFSA-Q-2012-00340) [10].
The claim proposed by the applicant was worded as follows: ‘OptiEFAX™ helps to maintain healthy blood levels of HDL cholesterol’.
Vložnik je predlagal naslednjo trditev: „OptiEFAX™ pomaga vzdrževati zdrave ravni HDL-holesterola v krvi.“
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of KF2BL20, which is a combination of keratin, copper, zinc, niacin, pantothenic acid, pyridoxine and D-biotin, and maintenance of normal hair (Question No EFSA-Q-2012-00381) [11].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki KF2BL20, mešanice keratina, bakra, cinka, niacina, pantotenske kisline, piridoksina in D-biotina na ohranjanje zdravih las (vprašanje št. EFSA-Q-2012-00381) [11].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to maintain hair strength’.
Vložnik je med drugim predlagal naslednjo trditev: „Pomaga ohraniti močne lase“.
On 17 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of KF2BL20 and the claimed effect.
Komisija in države članice so 17. julija 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem KF2BL20 in navedeno trditvijo ni utemeljena.
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of hyaluronic acid and protection of the skin against dehydration (Question No EFSA-Q-2012-00382) [12].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki hialuronske kisline na zaščito kože pred dehidracijo (vprašanje št. EFSA-Q-2012-00382) [12].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to maintain good skin hydration’.
Vložnik je med drugim predlagal naslednjo trditev: „Pomaga ohraniti dobro hidracijo kože“.
On 17 July 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of hyaluronic acid and the claimed effect.
Komisija in države članice so 17. julija 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem hialuronske kisline in navedeno trditvijo ni utemeljena.
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of OptiEFAX™ and maintenance of normal blood concentrations of triglycerides (Question No EFSA-Q-2012-00383) [13].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki OptiEFAX™ na vzdrževanje normalne koncentracije trigliceridov v krvi (vprašanje št. EFSA-Q-2012-00383) [13].
The claim proposed by the applicant was worded as follows: ‘OptiEFAX™ helps to maintain healthy blood levels of triglycerides.’
Vložnik je predlagal naslednjo trditev: „OptiEFAX™ pomaga vzdrževati zdrave ravni trigliceridov v krvi.“
Following an application from Vivatech, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Transitech® and ‘improves transit and durably regulates it’ (Question No EFSA-Q-2012-00296) [14].
Družba Vivatech je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Transitech® na „izboljšanje in trajno uravnavanje prehajanja črevesne vsebine“ (vprašanje št. EFSA-Q-2012-00296) [14].
The claim proposed by the applicant was worded as follows: ‘Improves transit and durably regulates it’.
Vložnik je predlagal naslednjo trditev: „Izboljša prehajanje črevesne vsebine in ga trajno ureja“.
On 26 September 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship could not be established between the consumption of Transitech® and the claimed effect.
Komisija in države članice so 26. septembra 2012 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledične povezave med uživanjem Transitech® in navedeno trditvijo ni bilo mogoče utemeljiti.
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Femilub® and maintenance of vaginal moisture (Question No EFSA-Q-2012-00571) [15].
Družba Nutrilinks Sarl je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki Femilub® na vzdrževanje vaginalne vlažnosti (vprašanje št. EFSA-Q-2012-00571) [15].
The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to reduce vaginal dryness’.
Vložnik je med drugim predlagal naslednjo trditev: „Pomaga zmanjšati vaginalno suhost“.